Article

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Blood (Impact Factor: 10.43). 03/2007; 109(6):2276-84. DOI: 10.1182/blood-2006-07-038430
Source: PubMed

ABSTRACT To molecularly define high-risk disease, we performed microarray analysis on tumor cells from 532 newly diagnosed patients with multiple myeloma (MM) treated on 2 separate protocols. Using log-rank tests of expression quartiles, 70 genes, 30% mapping to chromosome 1 (P < .001), were linked to early disease-related death. Importantly, most up-regulated genes mapped to chromosome 1q, and down-regulated genes mapped to chromosome 1p. The ratio of mean expression levels of up-regulated to down-regulated genes defined a high-risk score present in 13% of patients with shorter durations of complete remission, event-free survival, and overall survival (training set: hazard ratio [HR], 5.16; P < .001; test cohort: HR, 4.75; P < .001). The high-risk score also was an independent predictor of outcome endpoints in multivariate analysis (P < .001) that included the International Staging System and high-risk translocations. In a comparison of paired baseline and relapse samples, the high-risk score frequency rose to 76% at relapse and predicted short postrelapse survival (P < .05). Multivariate discriminant analysis revealed that a 17-gene subset could predict outcome as well as the 70-gene model. Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions.

Download full-text

Full-text

Available from: Michele Fox, Jul 06, 2015
0 Followers
 · 
282 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) is an incurable B-cell malignancy. The proteasome inhibitor bortezomib (BTZ) is a frontline MM drug; however, intrinsic or acquired resistance to BTZ remains a clinical hurdle. As BTZ induces oxidative stress in MM cells, we queried if altered redox homeostasis promotes BTZ resistance. In primary human MM samples, increased gene expression of copper-zinc superoxide dismutase (CuZnSOD or SOD1) correlated with cancer progression, high-risk disease, and adverse overall and event-free survival outcomes. As an in vitro model, human MM cell lines (MM.1S, 8226, U266) and the BTZ-resistant (BR) lines (MM.1SBR, 8226BR) were utilized to determine the role of antioxidants in intrinsic or acquired BTZ-resistance. An up-regulation of CuZnSOD, glutathione peroxidase-1 (GPx-1), and glutathione (GSH) were associated with BTZ resistance and attenuated prooxidant production by BTZ. Enforced overexpression of SOD1 induced BTZ resistance and pharmacological inhibition of CuZnSOD with disulfiram (DSF) augmented BTZ cytotoxicity in both BTZ-sensitive and BTZ-resistant cell lines. Our data validates CuZnSOD as a novel therapeutic target in MM. We propose DSF as an adjuvant to BTZ in MM that is expected to overcome intrinsic and acquired BTZ resistance as well as augment BTZ cytotoxicity. Published by Elsevier B.V.
    11/2014; 4C:23-33. DOI:10.1016/j.redox.2014.11.002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Motivation: The successful translation of genomic signatures into clinical settings relies on good discrimination between patient sub-groups. Many sophisticated algorithms have been proposed in the statistics and machine learning literature, but in practice simpler algorithms are often used. However, few simple algorithms have been formally described or systematically investigated. Results: We give a precise definition of a popular simple method we refer to as mas-o-menos, which calculates prognostic scores for discrimination by summing standardized predictors, weighted by the signs of their marginal associations with the outcome. We study its behavior theoretically, in simulations and in an extensive analysis of 27 independent gene expression studies of bladder, breast and ovarian cancer, altogether totaling 3833 patients with survival outcomes. We find that despite its simplicity, mas-o-menos can achieve good discrimination performance. It performs no worse, and sometimes better, than popular and much more CPU-intensive methods for discrimination, including lasso and ridge regression.
    Bioinformatics 07/2014; 30(21). DOI:10.1093/bioinformatics/btu488 · 4.62 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although multiple myeloma still remains an incurable disease, the introduction of new drugs like thalidomide, bortezomib and lenalidomide, and recently carfilzomib and pomalidomide (not in the EU) has significantly prolonged life of patients with multiple myeloma. One of the key factors affecting the dramatic improvement in the effectiveness of the therapy is the development of so-called translational research which is defined by intensive laboratory work, mainly based on molecular studies, focused on the extremely fast introduction of this knowledge in clinical practice. The use of modern methods of molecular biology by identifying new therapeutic targets in preclinical studies has allowed the introduction of new particles such as perifosine or elotuzumab for clinical trials, which will probably result in their rapid introduction into everyday clinical practice. “Translational research” is also used in the work on the optimization of treatment with substances already registered as exemplified by studies using GEP and proteomics. Consolidated and consistent actions of hematological centers in Poland, in cooperation with the Polish non-clinical research centers, as well as with foreign institutions, given the large clinical population of patients with multiple myeloma, it is a huge Polish opportunity to develop knowledge about the disease. This will give a chance to people for easier access to modern forms of therapy to ultimately make myeloma from “incurable” to “chronic” disease.
    Acta haematologica Polonica 07/2013; 44(3):196–199. DOI:10.1016/j.achaem.2013.07.007